


-33-

Claims

1. A compound of the formula I:



5

Formula I

wherein:

10 **Z** is selected from N and CH;

W is selected from N and CH;

X is selected from NH and CH₂;

Y is selected from F, Cl, Br and I; and

n is 1, 2 or 3;

15 and salts or solvates thereof.

2. A compound of the formula I according to claim 1, wherein **Z** is N, and salts or solvates thereof.

20 3. A compound of the formula I according to claim 1 or claim 2, wherein **Y** is selected from F and/or Cl, and salts or solvates thereof.

4. A compound of the formula I according to claim 1, selected from one or more of the following:

25 *N*-{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(3-fluorophenyl)urea;

-34-

- N*-{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(2-fluorophenyl)urea;
- N*-{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(3-chlorophenyl)urea;
- 5 *N*-{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(2-chlorophenyl)urea;
- N*-{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(3-fluorophenyl)acetamide;
- N*-{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-
- 10 2-(2-fluorophenyl)acetamide;
- N*-{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(3-chlorophenyl)acetamide;
- N*-{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2'-(2-chlorophenyl)acetamide;
- 15 *N*-{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(3-fluorophenyl)urea;
- N*-{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(2-fluorophenyl)urea;
- N*-{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(3-
- 20 chlorophenyl)urea;
- N*-{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(2-chlorophenyl)urea;
- N*-{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(3-fluorophenyl)acetamide;
- 25 *N*-{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(2-fluorophenyl)acetamide;
- N*-{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(3-chlorophenyl)acetamide;
- N*-{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-
- 30 2-(2-chlorophenyl)acetamide;
- and salts or solvates thereof.

-35-

5. A pharmaceutical composition comprising a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 4 in association with a pharmaceutically acceptable diluent or carrier.


5 6. A compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 4 for use as a medicament.

7. Use of a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 4, in the manufacture of a medicament for use as a Tie2
10 receptor tyrosine kinase inhibitor in a warm-blooded animal such as man.


8. Use of a compound of the formula I, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 4, in the manufacture of a medicament for use in the production of an anti-angiogenic effect in a warm-blooded animal such as man.

15

9. A process for preparing a compound of formula I, or a salt or solvate thereof, wherein X is NH and Z, W, Y and n are as defined in formula I, which process comprises of reacting an amine of the formula II with an isocyanate of the formula III and thereafter if necessary:



Formula II



Formula III

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) forming a salt or solvate.

25